Month: February 2024

Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development...

Contacts Christopher C. King, VP, Investor Relations Billie-Jo McIntire, AVP, Investor Relations (410) 568-1500 Sinclair, Inc. (Nasdaq: SBGI) announced that...

– Q4 and full year 2023 product revenue (DAXXIFY® and RHA® Collection) of $58.5 million and $212.7 million, representing approximately...

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in...

Contacts Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Nathanson 332-239-2660 | info@bgandg.com Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC...

SAN CARLOS, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Oportun (Nasdaq: OPRT), a mission-driven fintech, will release financial results for...

EVANSVILLE, Ind., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Old National Bancorp (NASDAQ: ONB) today announced that Chairman and Chief Executive...

Contacts Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc., 510-826-2350 Media Lesley Bogdanow, VP of Corporate Communications, Natera, Inc.,...

Reports 26% YoY ARR Growth and Strong Free Cash Flow Delivers Outperformance Across All Second Quarter Guided Metrics Contacts Investor...

LUXEMBOURG, Feb. 28, 2024 (GLOBE NEWSWIRE) -- NeoGames S.A. (Nasdaq: NGMS) (“NeoGames” or the "Company"), a technology-driven provider of end-to-end...

THORNTON, Colo., Feb. 28, 2024 (GLOBE NEWSWIRE) -- MYR Group Inc. (“MYR”) (NASDAQ: MYRG), a holding company of leading specialty...

-   Petosemtamab in 1L HNSCC in combination with pembrolizumab initial interim clinical data planned for 2Q24; preparing for a potential...

The global modern card issuing platform had $62 billion in fourth quarter total processing volume, up 33 percent year-over-year, and...

-- Record Fourth Quarter Net Sales Rise 14.4 Percent to $1.73 Billion ---- Net Sales, Adjusted for Adverse Changes in...

Contacts Investor Information: Cody Slach or Alex Thompson Gateway Group 949.574.3860 hear@gateway-grp.com Public Relations & Media: MacLean Marshall Sr. Director,...

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- EverQuote, Inc. (Nasdaq: EVER), a leading online insurance marketplace, today announced that...

ATHENS, Greece, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Euroseas Ltd. (NASDAQ: ESEA, the “Company” or “Euroseas”), an owner and operator...

Fourth quarter revenue grew 9% year-over-year to $65.9 millionFull year 2023 revenue grew 13% year-over-year to $251.4 million Read more at...

Company Updates 2024 Revenue Guidance to $720-$750 Million, Introduces 2024 Adjusted EBITDA Guidance1 of $80-$85 Million Management to Host Conference...

Full-year 2023 revenue of $220 million, an increase of 60% compared to 2022 and above previously reported guidance Delivered 70,429...

Phase 3 PATHFNDR-2 Study Topline Results Expected in March 2024; Pending Results, NDA Submission in Acromegaly Anticipated 2H 2024Phase 2...

Q4 2023 Net Sales, Net Income, Adjusted EBITDA and EPS Increase to Record LevelsFY 2023 Net Sales Increased 16% to a...

Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID™Recently Announced Debt Financing...

Contacts Investor Relations Cadence Design Systems, Inc. 408-944-7100 investor_relations@cadence.com Cadence Design Systems, Inc. (Nasdaq: CDNS): WHO: Anirudh Devgan, president and...

Delivered Total Revenue of $280.3 Million, Exceeding the High End of Updated Guidance for 2023 Grew Testing Services Results for...

Contacts Investor Relations Contact: Darby Schoenfeld, CPA Senior Vice President, Investor Relations 877-497-7497 investorrelations@pathward.com Pathward Financial, Inc. (Nasdaq: CASH) and...

- Fourth Quarter 2023 Total Revenues Grew 16% Year-Over-Year to $284.6 Million - - Full Year 2023 Total Revenues Grew...

Contacts Investor Contact ir@team.bumble.com Media Contact press@team.bumble.com Bumble Inc. (NASDAQ: BMBL) today announced that management will participate at the following...

- Q4 2023 Net Income of $14.6 Million, or $2.16 per Diluted Share - - Full Year 2023 Net Income...

Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV...

Sales grew 23.5% to $195.3 million in the quarter and were up 28.8% to $689.2 million for the full year...

WESTLAKE VILLAGE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing...

PLANO, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Alkami Technology, Inc. (Nasdaq: ALKT) (“Alkami”), a leading cloud-based digital banking solutions...

REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use...

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- AdTheorent Holding Company, Inc. (“AdTheorent” or the “Company”) (Nasdaq: ADTH), a machine...

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the...

BEVERLY, Mass., Feb. 28, 2024 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions...

SEATTLE, Feb. 28, 2024 /PRNewswire/ -- Zillow Group, Inc. (Nasdaq: Z and ZG), which is transforming the way people buy,...

Contacts Charles Liles cliles@xencor.com (626) 737-8118 Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of...